Cholamandalam Finance Q1 Review - Demand Growing, Provision Roll-Backs Likely In H2 FY22E: Systematix
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Systematix Research Report
Cholamandalam Investment and Finance Company Ltd. reported a profit of Rs 3.3 billion in Q1 FY22 due to higher provisions.
With a normalizing Covid-19 situation and better customer cash flows, provision roll-backs are likely in H2 FY22E.
Cholamandalam’s stage-III provision is at 35.5%, which seems prudent.
Disbursements and collections are bouncing back to pre-Covid-19 levels.
We remain sanguine about the disbursement run-rate bouncing back to pre-Covid levels in FY22E.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.